Clinical Trial Update: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol [Phase 2]

View source ↗

Summary

Phase 2 trial comparing preoperative trastuzumab and pertuzumab with versus without concurrent taxane chemotherapy in operable HER2-positive, HR-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED